GTX-104 + Nimotop 30 MG Oral Capsule
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Trial Timeline
Oct 20, 2023 → Dec 1, 2024
NCT ID
NCT05995405About GTX-104 + Nimotop 30 MG Oral Capsule
GTX-104 + Nimotop 30 MG Oral Capsule is a phase 3 stage product being developed by Grace Therapeutics for Aneurysmal Subarachnoid Hemorrhage (aSAH). The current trial status is active. This product is registered under clinical trial identifier NCT05995405. Target conditions include Aneurysmal Subarachnoid Hemorrhage (aSAH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05995405 | Phase 3 | Active |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage (aSAH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erythropoietin beta | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan | Idorsia | Phase 2 | 47 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 2 | 47 |
| GTX-104 + Nimodipine Capsules | Grace Therapeutics | Phase 1 | 25 |